New Ophthalmic Drug and Device Approvals Worth Knowing for Vivas

Drug and device approvals are jurisdiction-specific, date-specific and indication-specific. In an ophthalmology viva, do not say “approved” unless you can state the regulator, country/region, date, intended population and source. A positive trial, a CE mark, a US approval and Indian availability are not interchangeable statements.

This is exam-education guidance, not prescribing, procurement or regulatory advice.

First, separate the words examiners deliberately blur

An approval is a regulator’s decision in a defined jurisdiction. An authorisation, label update, safety communication, clearance, CE-mark-related claim, recommendation, tender, local formulary listing and commercial launch are different events. A phase 3 result may be important evidence without being an approval. A device may have a regulatory pathway different from a medicine. A medicine available in one country may not be licensed, supplied or affordable in another.

In a viva, say which proposition you are making. “This agent has positive trial data” is not the same as “this regulator approved it for this labelled population.” “This platform is used in a centre” is not the same as “it is cleared for autonomous diagnosis.” Precision is safer than a long, stale list of brand names.

Use this short opening when the stem is vague: “I would first confirm the jurisdiction, date and exact labelled indication; I will describe the mechanism and evidence framework, but I would not assume availability or approval from a foreign regulator.” That answer demonstrates regulatory literacy without pretending to know a mutable database by memory.

The 30-second approval answer

Use this sequence:

1. Name the condition and clinical setting.
2. Identify the drug or device class and mechanism/principle.
3. State the regulator and jurisdiction, with the date checked.
4. Give the approved indication, not a broad disease label.
5. Name the pivotal evidence at a high level.
6. Finish with one limitation: eligibility, safety monitoring, follow-up, access, cost or uncertain real-world performance.

If you cannot verify points 3 and 4, say: “I would check the current regulator’s record before calling this approved in this jurisdiction.” That is safer than importing a foreign approval into an Indian exam answer.

Build a current-viva card

Keep the source URL on the card. Recheck it in the week before a viva. A review article can explain background but should not be your final evidence for a current approval claim.

The source hierarchy for a current claim

Start with the regulator rather than a manufacturer press release or a social-media post. In the United States, FDA Drugs@FDA and device databases are starting points; the European Medicines Agency provides medicine information for its remit; Indian regulatory status should be checked from the current CDSCO source and the relevant official record.¹²³ These portals do not make a universal list: each has a jurisdiction, product category and search method.

Then open the current prescribing information, decision summary or device documentation where available. It can tell you what the regulator actually authorised, which population was studied or labelled, and key warnings/limitations. Only after that should you use the pivotal trial paper to explain evidence. A journal abstract may omit label restrictions; a label may not explain trial design in enough detail for a viva. Use both, but do not let either stand in for the other.

For a device, add two questions: what is the intended use? and who is expected to operate or interpret it? A machine-learning report that performs well on a dataset is not automatically a device authorised for independent use in all settings. A surgical device’s existence does not prove that it is available, affordable or appropriate for every patient. Those are separate claims requiring current local evidence.

A mechanism-first map of the kinds of advances you may be asked about

This is a study map, not a list of current approvals. It lets you discuss a new intervention without incorrectly asserting its regulatory status.

The safest phrase is “the mechanism under investigation/used by the class is …” unless you have the current product-specific label open. The exact indication and warning section can change and should never be reconstructed from a revision note.

How to answer a named-drug viva without overclaiming

Suppose the examiner names a recently discussed therapy. Work through the following in order:

1. Identify the clinical problem. State the disease, stage or treatment context given in the stem—not merely “retina” or “glaucoma.”
2. Name the class and mechanism. Keep it at the level supported by the source.
3. Locate the jurisdiction. Ask whether the question concerns FDA, EMA, CDSCO or another named regulator.
4. State the current source boundary. If you have not verified the record, say you would check the regulator’s label/decision database before calling it approved.
5. Describe evidence carefully. Trial design, comparator, endpoint and follow-up are stronger than “it works.”
6. Add a limitation. Safety, monitoring, delivery, durability, selection, access or implementation can be appropriate, but do not invent a contraindication.

This sequence also works for “What is new?” questions. A candidate need not recite every headline. A precise, bounded answer about one therapy or device is superior to a list that blends experimental work, foreign approval and local availability.

Four common viva errors

Avoid four common viva errors

• Calling a trial result an approval.
• Turning approval in one country into worldwide availability.
• Naming a drug without its indication or safety limitation.
• Treating an algorithm’s validation paper as permission for independent clinical use.

A fifth error is date blindness. A source may be accurate on the day it is published and stale when you sit the examination. Write the access date on your card. For a scheduled viva, recheck the official record in the preceding week and remove any claim you cannot substantiate. If the question is historical, state the historical date explicitly; if it is current, use a current official source.

What to do when two sources disagree

First identify whether they are answering the same question. A trial registry may show that a study is recruiting; a journal paper may report interim efficacy; a regulator label may have a narrower population; a hospital website may announce local access. These can all be true at once. They do not support the same conclusion.

Make a small conflict table: source, jurisdiction, date, intervention, proposition, and what it actually proves. Give priority to the current regulator record for a regulatory-status claim, the current label/decision document for authorised use, and the primary study for trial methods and endpoints. If the dates, populations or jurisdictions differ, say so rather than forcing a winner. A conflicting source is often evidence that your one-line claim is too broad.

For viva preparation, the correct conclusion can be: “The evidence base is evolving, but I would not call this approved in our jurisdiction until the current official record confirms it.” This is more defensible than implying that every innovation has a settled place in clinical practice. It also keeps the answer within education rather than prescribing or procurement advice.

A 15-minute update routine

Choose no more than five interventions relevant to your forthcoming exam. For each, save one regulator record, one current label/decision page where available and one pivotal or high-quality evidence source. Record the jurisdiction and access date. On a second card, write only: condition, class/principle, regulator source, evidence endpoint and one limitation. Do not copy a price, launch date, availability statement or eligibility criterion unless you have a current official reason to need it.

The routine is intentionally small. A well-maintained five-card file is more useful than an unverified “2026 updates” document. If a source changes, update the card or mark it unknown. That is not a weakness; it is the correct response to changing regulatory information.

Before the viva, practise one answer aloud in under 30 seconds and one in two minutes. The short version should identify the condition, class, jurisdiction check and one limitation. The longer version can add study design and endpoint. If you cannot state the source boundary clearly, the card needs another check—not another marketing phrase.

Do not confuse this caution with ignorance. Regulatory and evidence language is part of modern ophthalmic literacy. The candidate who distinguishes a regulator decision from a trial, a label from availability, and a device’s intended use from an aspirational workflow is demonstrating judgement. That judgement remains useful even when the named intervention changes next year or next month.

The American Academy of Ophthalmology education catalogue is a verified .org learning-resource directory. Use regulator and label sources for status questions; the catalogue does not establish current approval status.

For drug-class and practical-viva revision, see Ophthalmology Drugs Practical PDF and Instruments & Drugs for Practical Exams/Viva. For broader recent-advances note revision, use Recent Advances in Ophthalmology.